Twist Bioscience Corporation Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
Twist Bioscience Corporation (TWST) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of $0 for the 9-month period ending 2024-06-30, per its 10-Q filed 2024-08-02.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2024-11-18
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2024-06-30 was $0.00.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2023 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-02 | $0.00 10-Q · filed 2024-08-02 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | |||
| 2023-09-30 | $0.00 10-K · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |